TITLE:
Comparison of Fulvestrant (FASLODEX) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

CONDITION:
Breast Cancer

INTERVENTION:
Fulvestrant

SUMMARY:

      The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant
      with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive
      advanced breast cancer who have failed on a previous endocrine treatment.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 45 Years to 130 Years
Criteria:

        Inclusion Criteria:

          -  Breast Cancer has continued to grow after having received treatment with an
             anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor

          -  Requiring hormonal treatment

          -  Postmenopausal women defined as a woman who has stopped having menstrual periods

          -  Evidence of positive estrogen receptor hormone sensitivity

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  Treatment with an investigational or non-approved drug within one month

          -  An existing serious disease, illness, or condition that will prevent participation or
             compliance with study procedures

          -  A history of allergies to any active or inactive ingredients of Faslodex (i.e. castor
             oil)

          -  Treatment with more than one regimen of chemotherapy for advanced breast cancer

          -  Treatment with more than one regimen of hormonal treatment for advanced breast cancer
      
